Allergy Immunotherapy Market – Global Industry Analysis and Forecast (2023-2029)

Allergy Immunotherapy Market is expected to reach USD 7.60 billion by 2029, with a CAGR of 11.38 % between 2022 and 2029.

The Allergy immunotherapy is a treatment that prevents allergic responses from a variety of sources, including food, grass pollen, dust, and bee venom. Allergy immunotherapy helps patients with allergies such as rhinitis, asthma, and conjunctivitis, among other allergens, regulate their symptoms. Using both qualitative and quantitative data, the study provides a thorough picture of the industry. It provides a thorough examination of the global Allergy Immunotherapy market, as well as forecasts for the major categories. For the years 2022 to 2029, it also provides market size and forecast estimations for five important regions: North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. Within each location, the Allergy Immunotherapy Market is further segmented by countries and sectors.To know about the Research Methodology:- Request Free Sample Report
Allergy Immunotherapy Market Dynamics:
The global allergy immunotherapy market is expected to grow in response to the growing incidence and prevalence of allergic illnesses. According to the Centers for Disease Control and Prevention, the United States had 19.2 million cases of hay fever in people 18 and older and 5.2 million cases in children under the age of 18 in 2021. Additionally, the worldwide allergy immunotherapy market is growing due to changing environmental conditions and rising pollution levels. According to the Asthma and Allergy Foundation of America (AAFA), ragweed pollen allergy affects roughly 23 million people in the United States. These sensations can make persons with allergies melancholy, and they can also exacerbate asthma symptoms in allergic asthma sufferers.

Over the forecast period, an increase in the number of pipeline goods is likely to fuel market growth.

Over the forecast period, an increase in the number of pipeline immunotherapy treatments for allergy treatment is likely to promote market growth and present significant opportunities for various firms. Sublingual immunotherapy has been studied for a range of food allergies, including milk, peanut, kiwi, and peach allergies, by some of researchers. These studies have proven that when a patient takes medicine on a regular basis, the therapy is effective. However, the impact of therapy after treatment has yet to be confirmed.

The global allergy immunotherapy market is expected to be hampered by a lack of patient knowledge regarding allergy immunotherapy. Another issue that is expected to limit market growth is the negative effects associated with allergy immunotherapy.
Allergy Immunotherapy Market Segmentation Analysis:
By Treatment Type, The Subcutaneous Immunotherapy (SCIT) segment, which is the most effective and widely used form of allergy immunotherapy, accounted for the greatest portion of the market in 2022, with a revenue of 1.1 billion dollars. SCIT has also proven to be useful in the treatment of several allergens. Thus, SCIT is widely used.

During the forecast period, the Sublingual Immunotherapy (SLIT) sector is predicted to grow at the quickest rate. For individuals who are unable to get allergy injections, SLIT is projected to become an important option. Odactra, Grazax, Oralair, and Ragwitek are some of the FDA-approved SLIT pills now available in the United States. In the future, liquid formulations are likely to be licenced for therapeutic use in the United States. This is expected to boost the growth of teh SLIT segment in the country.
Allergy Immunotherapy Market Regional Insight
During the forecast period, the global, Europe is expected to be the largest regional market for allergy immunotherapy, accounting for more than half of the global market value. The region's supremacy can be ascribed to the fact that it has a large population with a variety of allergies. According to the European Academy of Allergy and Clinical Immunology (EAACI), chronic food allergies affect about 150 million individuals in Europe, accounting for 20% of the population.

Additionally, by 2029, 50 % of Europe's population will be allergic, presenting a profitable development opportunity for the allergy immunotherapy business, according to the organisation.

Despite having a lesser share than Europe, North America will remain the second most lucrative area during the forecast period. Because of the high incidence of allergies in the area, the United States is likely to continue at the forefront of the North American market, accounting for the bulk of market value. Additionally, allergies are more common in youngsters. According to the National Health Interview Survey (NHIS), 8.4% of children under the age of 18 in the United States had allergic rhinitis, 10% had respiratory allergies, 5.4 percent had food allergies, and 11.6 percent had skin allergies in 2017.

The United States is likely to be the world's second largest market for allergy immunotherapy. The high incidence of allergies in the United States, as well as strict regulatory rules that require allergic testing in all cases of acute and emergency care, are driving the growth of the allergy immunotherapy industry in the United States. According to the figures (2022)of the Asthma and Allergy Foundation, one out of every six Americans (about 50 million) suffers from some sort of allergy, with over 25 million Americans suffering from respiratory allergies.

Report Objectives:

Landscape analysis of the Allergy Immunotherapy Market

competitive benchmarking

Past and current status of the industry with the forecasted market size and trends

Evaluation of potential key players that include market leaders, followers, and new entrants

Technology trends

The potential impact of micro-economic factors on the market

External and Internal factors affecting the market have been analyzed

The report also helps in understanding the Allergy Immunotherapy Market dynamics, and structure by analyzing the market segments to project the Allergy Immunotherapy Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Allergy Immunotherapy Market make the report investor’s guide.
Allergy Immunotherapy Market Scope: Inquire before buying



Global Allergy Immunotherapy Market


Report Coverage
Details


Base Year:
2022
Forecast Period:
2023-2029


Historical Data:
2018 to 2022
Market Size in 2022:
US $ 3.57 Bn.


Forecast Period 2023 to 2029 CAGR:
11.38 %
Market Size in 2029:
US $ 7.60 Bn.


 Segments Covered:
by Treatment Type
Subcutaneous Immunotherapy (SCIT)
Sublingual Immunotherapy (SLIT)
   Tablets
   Drops


by Allergy Type
Allergic rhinitis
Allergic asthma
Others


by Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy



Allergy Immunotherapy Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest)
Key Players  are :
1. Aimmune Therapeutics
2. ALK-Abello A/S
3. Stallergenes Greer
4. Allergy Therapeutics
5. Biomay AG
6. Merck KGaA
7. DBV Technologies
8. Circassia
9. WOLW Pharma
10.Holister Stier
11.HAL Allergy Group
12.Anergis.
13.ASIT Biotech
14.Mylan N.V.
15.Adamis Pharmaceuticals Corporation
16.DESENTUM OY
17.LETIPharma
18.Anergis SA
Frequently Asked Questions
1. What is the projected market size & growth rate of the Allergy Immunotherapy Market?
Ans- The market was valued at USD 3.57 billion in 2022 and is projected to reach USD 7.60 billion by 2029, growing at a CAGR of 11.38 % during the forecast period.

2. What is the key driving factor for the growth of the Allergy Immunotherapy Market?
Ans- The global market is expected to grow in response to the growing incidence and prevalence of allergic illnesses.

3. Which Region accounted for the largest Allergy Immunotherapy Market share?
Ans- Europe accounted for the largest share in 2022.

4. What makes the Europe a Lucrative Market for Allergy Immunotherapy Market?
Ans- The region's supremacy can be ascribed to the fact that it has a large population with a variety of allergies.

5. What are the top players operating in the Allergy Immunotherapy Market?
Ans- Aimmune Therapeutics, ALK-Abello A/S, Stallergenes Greer, Allergy Therapeutics, and Biomay AG